Cannara Biotech Inc. reported earnings results for the full year ended August 31, 2022. For the full year, the company reported sales was CAD 3.37 million compared to CAD 3.12 million a year ago. Revenue was CAD 36 million compared to CAD 17.27 million a year ago.

Net income was CAD 2.31 million compared to net loss of CAD 1.53 million a year ago. Basic earnings per share from continuing operations was CAD 0.01 compared to basic loss per share from continuing operations of CAD 0.1 a year ago. Diluted earnings per share from continuing operations was CAD 0.01 compared to diluted loss per share from continuing operations of CAD 0.1 a year ago.